NVAX

Novavax, Inc. is a leading biotechnology firm based in Gaithersburg, Maryland, renowned for its pioneering approach to vaccine development against critical infectious diseases. Utilizing its proprietary protein-based nanoparticle technology, Novavax has established a strong pipeline that includes its advanced COVID-19 vaccine candidate, garnering significant interest in the context of global health challenges. The company's strategic alliances and dedication to innovative health solutions underscore its potential to impact public health significantly, making it an attractive investment for institutional investors focused on the biotechnology sector.